Wanbury Limited has informed the Exchange regarding Board meeting held on May 15, 2025.
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.3 pts more than Nifty Microcap 250 and 8.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Wanbury Limited's board approved audited standalone and consolidated financial results for Q4 and FY25 on May 15, 2025. Full-year revenue from operations grew about 3.8% to ₹59,951 lakhs (vs ₹57,774 lakhs in FY24), while profit after tax was largely flat at ₹3,053 lakhs (vs ₹3,040 lakhs). Q4 FY25 was much stronger, with revenue up roughly 23% to ₹17,200 lakhs and PAT of ₹2,026 lakhs (vs ₹808 lakhs), aided by a deferred tax reversal of about ₹706 lakhs. The company raised ₹17,500 lakhs via secured non-convertible debentures to refinance high-cost debt, fund capex and meet working capital needs. Both manufacturing plants were shut for about 40 days for upgrades, and the Patalganga facility cleared a USFDA inspection with zero observations. Auditor Kapoor & Parekh Associates issued an unmodified opinion.
Annual profits were flat despite modest revenue growth, and finance costs jumped 27% YoY, weighing on margins. The ₹17,500 lakh NCD issuance increases leverage and debt-servicing burden, though it is being used to retire costlier borrowings. The strong Q4 numbers, clean USFDA inspection, and improved other equity (from negative ₹480 lakhs to positive ₹2,650 lakhs) are positives, but shareholders should watch for recovery in operating profitability.